Systematic review, meta-analysis and economic modelling of ...

DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 135. Brooks S.P GA. Alternative methods for monitoring convergence of iterative simulations. J ComputGraph Stat 1998;7:434–45.36. Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acutemyocardial infarction. Am J Emerg Med 2006;24:149–55.37. Eggers KM, Ellenius J, Dellborg M, Groth T, Oldgren J, Swahn E, et al. Artificial neural networkalgorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chestpain patients. Int J Cardiol 2007;114:366–74.38. Kurz K. Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnTfor early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol2011;100:209–15.39. Macdonald SP, Nagree Y, Macdonald SPJ, Nagree Y. Rapid risk stratification in suspected acutecoronary syndrome using serial multiple cardiac biomarkers: a pilot study. Emerg Med Australas2008;20:403–9.40. Ooi S. Incremental value of heart-type fatty acid-binding protein, myoglobin, troponin T andelectrocardiogram in rapid bedside diagnosis of acute coronary syndrome in chest pain patientspresenting to the emergency department. Society for Academic Emergency Medicine AnnualMeeting 2007. Acad Emerg Med 2007;14:S131.41. Rathore S, Knowles P, Mann AP, Dodds PA, Rathore S, Knowles P, et al. Is it safe to dischargepatients from accident and emergency using a rapid point of care Triple Cardiac Marker test to ruleout acute coronary syndrome in low to intermediate risk patients presenting with chest pain? Eur JIntern Med 2008;19:537–40.42. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski J. Role of ‘Ischemia Modified Albumin’, a newbiochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes.Emerg Med J 2004;21:29–34.43. Eggers KM, Oldgren J, ld A, Lindahl B, Eggers KM, Oldgren J, et al. Combining different biochemicalmarkers of myocardial ischemia does not improve risk stratification in chest pain patients comparedto troponin I alone. Coron Artery Dis 2005;16:315–19.44. Eggers KM, Kempf T, Venge P, Wallentin L, Wollert KC, Lindahl B, et al. Improving long-term riskprediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE)risk score is enhanced by selected non-necrosis biomarkers. Am Heart J 2010;160:88–94.45. Mockel M, Muller R, Vollert JO, Muller C, Danne O, Gareis R, et al. Lipoprotein-associatedphospholipase A for early risk stratification in patients with suspected acute coronary syndrome: amulti-marker approach. Clin Res Cardiol 2007;96:604–12.46. Body R, Phil P. Low soluble P-selectin may facilitate early exclusion of acute myocardial infarction.Clin Chim Acta 2011;412:614–18.47. Brown AM, Wu AH, Clopton. ST2 in emergency department chest pain patients with potentialacute coronary syndromes. Ann Emerg Med 2007;50:153–8.48. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, et al. Utility of admissioncardiac troponin and ‘ischemia modified albumin’ measurements for rapid evaluation andrule out of suspected acute myocardial infarction in the emergency department. Emerg Med J2006;23:256–61.49. Garcia-Valdecasas S, Ruiz-Alvarez MJ, Garcia DT, De Pablo. Diagnostic and prognostic value ofheart-type fatty acid-binding protein in the early hours of acute myocardial infarction. Acta Cardiol2011;66:315–21.50. Ilva T, Lund J, Porela P, Mustonen H, Voipio-Pulkki LM, Eriksson S, et al. Early markers of myocardialinjury: cTnI is enough. Clin Chim Acta 2009;400:82–5.© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.123